Leerink Partners analyst Mani Foroohar reiterated an Outperform rating and $45.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

TD Cowen Reiterates Hold Rating on Sarepta Therapeutics (SRPT)July 21, 2025 6:55 AM BofA Securities Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)July 21, 2025 6:03 AM Baird Downgrades Sarepta Therapeutics (SRPT) to Neutral, 'Transparency Issues and Elevidys Uncertainty'July 18, 2025 2:19 PM Sarepta Therapeutics (SRPT) PT Lowered to $20 at BofA Securities, 'Safety reports could limit uptake of SRPT’s gene therapies'July 18, 2025 9:42 AM Morgan Stanley Reiterates Equalweight Rating on Sarepta Therapeutics (SRPT)July 18, 2025 9:33 AM Goldman Sachs Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)July 18, 2025 8:59 AM William Blair on Sarepta Therapeutics (SRPT): 'we continue to view the stock’s near-term upside potential as limited'July 18, 2025 8:58 AM Sarepta Therapeutics (SRPT) PT Lowered to $41 at OppenheimerJuly 18, 2025 8:34 AM Sarepta shares tumble after report of patient death in early-stage trialJuly 18, 2025 6:54 AM Sarepta Therapeutics (SRPT) PT Raised to $28 at TD CowenJuly 18, 2025 5:44 AM SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJuly 17, 2025 4:02 PM Sarepta Therapeutics (SRPT) PT Lowered to $23 at RBC CapitalJuly 17, 2025 10:28 AM Sarepta Therapeutics (SRPT) PT Lowered to $32 at Piper SandlerJuly 17, 2025 10:24 AM Cantor Fitzgerald Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)July 17, 2025 8:33 AM Needham Reiterates Buy Rating on Sarepta Therapeutics (SRPT)July 17, 2025 7:11 AM Sarepta Therapeutics (SRPT) PT Raised to $35 at BairdJuly 17, 2025 7:09 AM Sarepta Therapeutics (SRPT) PT Lowered to $65 at Wells FargoJuly 17, 2025 7:07 AM H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)July 17, 2025 6:48 AM Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)July 17, 2025 6:42 AM Sarepta Therapeutics (SRPT) PT Raised to $32 at BarclaysJuly 17, 2025 4:29 AM ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPTJuly 16, 2025 4:58 PM After-hours movers: United Airlines, Sarepta Therapeutic, MP MaterialsJuly 16, 2025 4:54 PM Form 8-K Sarepta Therapeutics, For: Jul 14July 16, 2025 4:11 PM Sarepta cuts 36% of workforce, expects $400M in annual savingsJuly 16, 2025 4:01 PM Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS LabelJuly 16, 2025 4:01 PM